Cytokine‑Driven Modulation of Immune Checkpoint Therapy Response in Colorectal Cancer.
Recent advances from preclinical studies are summarized and the potential of cytokines, as both the activators and inhibitors, to modulate drug resistance are explored to help guide the development of combinational immunotherapeutic strategies aimed at enhancing patient responses to ICIs in CRC.